Study #NCI10145
NCI10145: Phase IB Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
MD Anderson Study Status
Not Accepting
Treatment Agent
Copanlisib, Nivolumab, Ipilimumab
Description
This phase Ib trial studies the side effects and best dose of copanlisib and nivolumab and side effects of copanlisib given together with nivolumab and ipilimumab in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or lymphoma. Copanlisib stops tumors from growing by blocking proteins that are known to be important for tumor cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving copanlisib together with nivolumab or with nivolumab and ipilimumab may work better in treating patients with solid tumors or lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-614-1563
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.